The short answer
TRIUMPH is Eli Lilly's Phase 3 clinical trial programme for retatrutide, enrolling more than 5,800 participants across obesity, type 2 diabetes and cardiovascular populations. TRIUMPH-4 reported first in December 2025, TRIUMPH-1 in May 2026 and TRIUMPH-2 and -3 in July 2026. All pivotal trials reported so far have met their primary endpoints.
Key facts
- Sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Total enrolment
- More than 5,800 participants
- First readout
- TRIUMPH-4, December 2025
- Pivotal obesity trial
- TRIUMPH-1 (NCT05929066), May 2026
- Headline result
- 28.3% mean reduction at 80 weeks (12 mg)
- Still outstanding
- Maintenance-dosing studies
What the programme covers
TRIUMPH is not a single trial but a set of registrations testing retatrutide in progressively harder populations. TRIUMPH-1 is the pivotal obesity study. TRIUMPH-2 addresses obesity with type 2 diabetes. TRIUMPH-3 addresses severe obesity with established cardiovascular disease. TRIUMPH-4 reported first, in December 2025. Full identifiers, endpoints and enrolment criteria are on ClinicalTrials.gov.
Readout timeline
The programme reported in sequence across roughly eight months. TRIUMPH-4 came first in December 2025. TRIUMPH-1 followed on 21 May 2026 with the headline obesity result. TRIUMPH-2 and TRIUMPH-3 reported together in July 2026, both meeting their primary endpoints in their respective comorbid populations.
- TRIUMPH-4: first readout, December 2025
- TRIUMPH-1: pivotal obesity, 21 May 2026, 2,339 randomised
- TRIUMPH-2: obesity with type 2 diabetes, July 2026
- TRIUMPH-3: severe obesity with established CVD, July 2026
- Maintenance-dosing studies: further readouts expected
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What TRIUMPH-1 reported
Across 2,339 randomised adults, mean weight reduction at 80 weeks was 19.0% on 4 mg, 25.9% on 9 mg and 28.3% on 12 mg, against 2.2% on placebo. A 104-week extension in 532 participants reported 30.3% mean reduction on 12 mg among those with baseline BMI of 35 or above. Gastrointestinal adverse events were common and discontinuation on the 12 mg arm was 11.3% against 4.9% on placebo.
Why maintenance data are the outstanding question
Several further Phase 3 readouts were expected across 2026, including studies of maintenance dosing (what happens when the dose is reduced or stopped after the reduction phase). Weight regain after discontinuation is the unresolved question across the entire incretin class, not just for retatrutide, and it is what the field is waiting on.
Regulatory position
Positive pivotal results do not confer authorisation. Retatrutide remains investigational in every jurisdiction. Lilly has indicated an intended FDA Biologics License Application in the first quarter of 2027. The dose arms described above are facts about a registered trial run under clinical supervision and are not handling guidance.
Frequently asked questions
Where can I find TRIUMPH trial results?
Trials are registered on ClinicalTrials.gov, with topline results issued by Lilly and peer-reviewed publication following database posting.
Have all the TRIUMPH trials reported?
No. The pivotal trials have reported, but further readouts including maintenance-dosing studies were still expected across 2026.
Does TRIUMPH mean retatrutide is approved?
No. It remains investigational everywhere; an FDA filing was signalled for Q1 2027.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- RefTRIUMPH-1 topline results: Eli Lillyinvestor.lilly.com
- RefTwo additional Phase 3 obesity trials. Eli Lillyinvestor.lilly.com
- TrialClinicalTrials.gov: NCT05929066clinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05929079). Retatrutide in type 2 diabetesclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05882045). Retatrutide + established CVDclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-4 (NCT05931367). Retatrutide once weeklyclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-5 (NCT06662383). Retatrutide vs tirzepatideclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268). Maintenance of weight reductionclinicaltrials.gov
- PubMedJastreboff AM et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023 (PMID 37366315)pubmed.ncbi.nlm.nih.gov
- PubMedRosenstock J et al., Retatrutide for people with type 2 diabetes. Lancet 2023 (PMID 37385280)pubmed.ncbi.nlm.nih.gov
- PubMedCoskun T et al., LY3437943: a novel triple glucagon, GIP and GLP-1 receptor agonist. Cell Metab 2022 (PMID 35985340)pubmed.ncbi.nlm.nih.gov
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More Retatrutide Research articles
- How One Peptide Engages Three ReceptorsGIPR, GLP-1R and GCGR belong to one receptor family, which is what makes a single-molecule triple agonist possible at all.
- Retatrutide and AlcoholNo interaction study exists for retatrutide specifically. What the GLP-1 class literature reports about alcohol, and why the honest answer is narrow.
- Is There a Retatrutide Tablet or Pill?No oral retatrutide exists in any trial or any market. Why a 39-residue peptide cannot simply be pressed into a tablet, and what is being sold under that name.
- Fake Retatrutide and What a Certificate Can ProvePurity, identity and quantity are three separate questions and most certificates answer one. What HPLC and mass spectrometry establish, and what neither does.
- Is Retatrutide Legal?Retatrutide holds no marketing authorisation anywhere, making it unapproved rather than controlled. Two separate legal regimes, constantly confused.